WallStreetZenWallStreetZen

NASDAQ: NBIX
Neurocrine Biosciences Inc Earnings & Revenue

NBIX past earnings growth

How has NBIX's earnings growth performed historically?
Company
462.69%
Industry
19.03%
Market
119.55%
NBIX's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
NBIX's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
NBIX's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

NBIX past revenue growth

How has NBIX's revenue growth performed historically?
Company
23.99%
Industry
9.9%
Market
15.78%
NBIX's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
NBIX's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
NBIX's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

NBIX earnings and revenue history

Current Revenue
$2.0B
Current Earnings
$369.7M
Current Profit Margin
18.7%

NBIX Return on Equity

Current Company
17.5%
Current Industry
13.6%
Current Market
28.2%
NBIX's Return on Equity (17.5%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when NBIX announces earnings.

NBIX Return on Assets

Current Company
12.1%
Current Industry
3%
NBIX is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

NBIX Return on Capital Employed

Current Company
17.2%
Current Industry
5%
NBIX has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

NBIX vs Pharmaceutical Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
NBIX$1.98B$497.00M$369.70M+30.76%+18.38%
VTRS$15.36B$3.35B-$56.10M+6.44%N/A
RDY$2.99B$904.61M$547.73M+6.52%N/A
CTLT$4.14B-$524.00M-$1.18B+10.79%N/A
TEVA$16.00B$1.64B-$493.00M-1.61%N/A

Neurocrine Biosciences Earnings & Revenue FAQ

What were NBIX's earnings last quarter?

On Invalid Date, Neurocrine Biosciences (NASDAQ: NBIX) reported Q1 2024 earnings per share (EPS) of $0.43, up 154.43% year over year. Total Neurocrine Biosciences earnings for the quarter were $43.40 million. In the same quarter last year, Neurocrine Biosciences's earnings per share (EPS) was -$0.79.

If you're new to stock investing, here's how to buy Neurocrine Biosciences stock.

What was NBIX's earnings growth in the past year?

As of Q2 2024, Neurocrine Biosciences's earnings has grown 462.69% year over year. This is 443.65 percentage points higher than the US Drug Manufacturers - Specialty & Generic industry earnings growth rate of 19.03%. Neurocrine Biosciences's earnings in the past year totalled $369.70 million.

What was NBIX's revenue last quarter?

On Invalid Date, Neurocrine Biosciences (NASDAQ: NBIX) reported Q1 2024 revenue of $515.30 million up 22.57% year over year. In the same quarter last year, Neurocrine Biosciences's revenue was $420.40 million.

What was NBIX's revenue growth in the past year?

As of Q2 2024, Neurocrine Biosciences's revenue has grown 23.99% year over year. This is 14.09 percentage points higher than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 9.9%. Neurocrine Biosciences's revenue in the past year totalled $1.98 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.